QIAGEN announces first installation of GeneReader next-generation sequencer in Malaysia

Food and Healthcare Press Releases Thursday September 28, 2017 09:30
KUALA LUMPUR, Malaysia--28 Sep--PRNewswire/InfoQuest

QIAGEN Biotechnology Malaysia Sdn Bhd today announced that it has installed the company's first GeneReader Next-Generation Sequencing (NGS) System in Malaysia. The installation of the GeneReader NGS System at Pathomics Health Sdn Bhd, a digital health care solution company in Kuala Lumpur, enables actionable insights to support research that will benefit the country's cancer research community.

"Pathomics Health is excited to be the lab with Malaysia's first GeneReader NGS System," said Dr Ron Tan, a scientific advisor to Pathomics Health, whose vision is to provide a new standard in cancer research by integrating smart histopathology imaging and genomics analysis. "The GeneReader NGS simplifies the NGS workflow and generates an interpreted result without hassle. We know that NGS technology has achieved outstanding success, posting breakthroughs in the life sciences, applied testing, pharma and molecular diagnostics. We are particularly pleased to offer GeneReader system's ability to explore a tumor's molecular nature more quickly and affordably than other platforms."

The GeneReader NGS System was installed at Pathomics Health to enable the company to provide sequencing services. The collaboration also aims to develop new integrative tools for use in cancer diagnosis and prognosis.

Pathomics Health and the University of Malaya intend to share and improve the application, understanding and available resources associated with molecular pathology, particularly its application to cancer, through their respective networks in academia and industry.

QIAGEN is the world's leading provider of "Sample to Insight" solutions. The company's GeneReader NGS System is the first complete "Sample to Insight" next-generation sequencing solution. Its workflow covers the entire sequencing process from sample prep to data interpretation. As a result, GeneReader NGS is simpler and more cost-effective for laboratories, allowing them to take advantage of NGS technologies that improve next-generation sequencing for research. "With QIAGEN's GeneReader NGS System, researchers and lab staff can now focus on their research not technical issues," said William Lin, QIAGEN's director of commercial operations for Southeast Asia. "We are pleased to have installed our first GeneReader system with Pathomics Health and look forward to seeing many outstanding results of its collaborations with cancer researchers across the country."

According to the World Health Organization, cancer is among the leading causes of morbidity and mortality worldwide. There were approximately 14 million new cases and 8.2 million cancer-related deaths around the world in 2012. Each year, more than 60 percent of the world's new cases occur in Africa, Asia, and Central and South America. These regions account of 70 percent of the world's cancer deaths.

One in four Malaysians will develop cancer by age 75 and roughly 100,000 Malaysians suffer from cancer each year, according to Deputy Health Minister Datuk Seri Dr Hilmi Yahaya. By the year 2020, it is expected that the incidence of cancer in Malaysia will increase by 15 percent.

The official opening of Pathomics Health is on October 5, 2017. If you are interested in attending the event or learning more about the GeneReader NGS System, kindly email Malaysia-Marketing@qiagen.com .
Photo - https://photos.prnasia.com/prnh/20170915/1943221-1
Logo - https://photos.prnasia.com/prnh/20170915/1943221-1LOGO

Latest Press Release

Texas Cardiac Arrhythmia Institute at St. David#s Medical Center draws cardiac experts from across the globe for EPLive 2018

On March 1 and 2, 2018, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its fourth international symposium on complex arrhythmias, EPLive 2018. Nearly 200 leaders in the field of electrophysiology (EP) from Europe, Asia...

Johnson Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.

Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan,...

Biotherm Hosts the First Biotherm Healing Summit

Biotherm hosted the first "Biotherm Healing Summit" on March 7. A symposium on the theme of skin & healing, focusing on major research that has evidenced the link between micro-organisms and skin health. Unveiling Life PlanktonTM, the healing...

Cardiologist Reccomends Top 3 Steps to Help Prevent Heart Disease in Thailand

Bangkok, In Thailand, an average of 150 people per day, or six people per hour die from heart disease according to the Ministry of Public Health who reported that from 2012 to 2016, the average number of deaths caused by heart disease was approximately...

Pilatus Clinical Services - German Subsidiary PCS GMBH Awarded WDL GDP Certificate

As part of Pilatus Clinical Services ongoing plans to strengthen its position in Europe and as part of establishing a Global footprint, the company has announced that following a recent inspection by the German regulatory authorities, its German...

Related Topics